



Auro Laboratories Limited

314, T. V. Industrial Estate, S.K. Ahire Marg,
Worli, Mumbai - 400 030. India
Tel. : + 91 22 6663 5456
Fax : +91 22 6663 5460
E-mail : auro@aurolabs.com
Web : www.aurolabs.com

Reg. Off. / Mfg. Unit :
K-56, M. I. D. C. Tarapur,
Dist. Palghar, Maharashtra - 401506.
CIN No. L33125MH1989PLC051910

Date: November11, 2021

To
BSE Limited,
Corporate Relationship Department,
PhirozeJeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Reg: Security Code No. 530233:

Sub: Outcome of the Board Meeting dated November11, 2021:

Dear Sir / Ma'am,

Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors at their Meeting held today (i.e. **Thursday, November11, 2021**), has transacted the following business:

- Approved the Un-Audited Standalone Financial Results of the Company for the quarter & half year ended on September 30, 2021 as recommended by the Audit Committee.

Pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, we are enclosing herewith the following:

- Un-Audited Standalone Financial Results for the quarter & half year ended September 30, 2021.
- Statement of Assets and Liabilities as on September 30, 2021.
- Cash-Flow Statement for the quarter & half year ended September 30, 2021.
- Limited Review Report received from the Statutory Auditor of the Company.

The Meeting of the Board commenced at 2.20p.m. and concluded at 3.15 p.m.


The results will be published in the newspaper pursuant to Regulation 47(1) (b) of SEBI (LODR) Regulations, 2015 in due course.

Kindly take the same on record and acknowledge.

Thanking You,

Yours Faithfully,

For **AURO LABORATORIES LIMITED**


SIDDHARTHA DEORAH
WHOLE TIME DIRECTOR
DIN: 00230796



Encl.: as above


AURO LABORATORIES LIMITED
CIN NO. :- L33125MH1989PLC051910

Regd. Office : K - 56 M.I.D.C INDUSTRIAL AREA, TARAPUR
BOISAR, DIST. PALGHAR 401506 , MAHARASHTRA

Tel.: +91-22-66635456 Fax:+91-22-66635460 Email. auro@aurolabs.com Web: www.aurolabs.com

ANNEXURE - I

PART - I		(Rs. In Lakhs)					
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2021							
Sr. No.	Particulars	3 Months ended	Preceding 3 Months ended	3 Months ended	Half year Ended		For the Year Ended
		30.09.2021 <i>(Unaudited)</i>	30.06.2021 <i>(Unaudited)</i>	30.09.2020 <i>(Unaudited)</i>	30.09.2021 <i>(Unaudited)</i>	30.09.2020 <i>(Unaudited)</i>	31.03.2021 <i>(Audited)</i>
1	Income from Operations						
	(a) Net Sales/Income from Operations (Net of excise duty)	1,031.58	1,053.00	1,535.36	2,084.58	2,757.82	5,425.18
2	Other Income	29.45	49.54	27.87	78.99	33.56	75.78
3	Total Revenue (1 + 2)	1,061.03	1,102.54	1,563.23	2,163.57	2,791.38	5,500.96
4	Expenses						
	a. Consumption of raw material	563.38	779.27	877.65	1,342.65	1,614.84	2,743.09
	b. Purchase of Stock-in-trade	0.36	1.09	19.20	1.45	20.43	21.03
	c. (Increase) / decrease in Finished Goods stock in trade and work in progress	37.55	(158.71)	0.26	(121.16)	1.16	90.71
	d. Employee benefits expense	147.93	137.53	140.29	285.46	266.49	603.62
	e. Finance Cost	15.44	11.09	7.95	26.53	15.92	45.83
	f. Depreciation and amortisation expenses	26.00	26.00	25.00	52.00	50.00	103.56
	g. Other Expenses	169.91	155.80	181.98	325.71	320.44	842.58
	Total Expenses (4)	960.57	952.07	1,252.33	1,912.64	2,289.28	4,450.42
5	Profit / (Loss) before exceptional and extraordinary items and tax (3 ± 4)	100.46	150.47	310.90	250.93	502.10	1,050.54
6	Exceptional items				-		
7	Profit / (Loss) before extraordinary items and tax (5 ± 6)	100.46	150.47	310.90	250.93	502.10	1,050.54
8	Extraordinary items		-	-	-	-	
9	Profit / (Loss) before tax (7 ± 8)	100.46	150.47	310.90	250.93	502.10	1,050.54
10	Tax expense		-	-	-	-	
	(a) Current tax expenses for current year	29.25	43.82	85.50	73.07	138.08	320.09
	(b) MAT credit (where applicable)		-	-	-	-	
	(c) Defferered tax		-	-	-	-	12.49
11	Profit / (Loss) for the period from continuing operation (9 ± 10)	71.21	106.65	225.40	177.86	364.02	717.96
12	Profit / (Loss) for discontinuing operations		-		-	-	
13	Tax expense of discontinuing operations		-		-	-	
14	Profit / (Loss) for discontinuing operation (after tax) (12 ± 13)	71.21	106.65	225.40	177.86	364.02	717.96
15	Other Comprehensive Income	(5.85)	8.53	(1.12)	(5.85)	(1.12)	1.76
16	Total Comprehensive Income for the period (14 ± 15)	65.36	115.18	224.28	172.01	362.90	719.72
17	Paid-up equity share capital (Face value of Rs. 10 each)	623.25	623.25	623.25	623.25	623.25	623.25
17	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year)		-	-	-	-	2,235.01
18	Earnings per share (EPS) (Face Value - Rs. 10 per Equity Shares):						
	(a) Basic	1.14	1.71	3.62	2.85	5.84	11.52
	(b) Diluted	1.14	1.71	3.62	2.85	5.84	11.52



Auro Laboratories Limited
Statement of Assets and Liabilities (Ind AS)

Particulars	(Rs. In Lakhs)	
	As at 30.09.2021	As at 31.03.2021
	Unaudited	Audited
A ASSETS		
1. Non-Current Assets		
(a) Property, Plant and Equipment	1,304.89	1,355.67
(b) Capital Work -in-Progress	97.40	13.40
(c) Investment Property	-	-
(d) Financial Assets		
(i) Investments	4.88	4.88
(ii) Loans	-	-
(iii) Others	-	-
(e) Other non-current assets - Capital Advance	-	-
2. Current assets		
(c) Inventories	498.43	254.67
(b) Financial Assets		
(i) Investments	-	-
(ii) Trade Receivables	607.84	729.90
(iii) Cash and cash equivalents	1,035.55	1,082.14
(iv) Bank balances other than (iii) above	714.92	371.49
(v) Loans	-	-
(vi) Others	512.95	377.13
(c) Other Current Assets	-	-
TOTAL ASSETS	4776.86	4189.28
B EQUITY AND LIABILITIES		
1. Equity		
(a) Equity Share Capital	623.25	623.25
(b) Other Equity	2,407.02	2,235.01
2. Liabilities		
(I) Non-Current Liabilities		
(a) Financial Liabilities	690.31	203.88
(i) Other Financial Liabilities	84.50	112.00
(b) Provisions		
(c) Deferred Tax Liabilities (Net)	168.40	168.40
(II) Current Liabilities		
(a) Financial Liabilities		
(i) Trade Payables	644.37	574.96
(b) Other Current Liabilities	82.72	166.88
(c) Provisions	76.29	104.90
(d) Current Tax Liabilities (net)	-	-
TOTAL EQUITY AND LIABILITIES	4776.86	4189.28

Notes:

- 1) The above unaudited financial results for the quarter ended 30th September, 2021 were reviewed by the Audit Committee and thereafter approved by the Board of Directors at meeting held on 5th November 2021.
- 2) Statement of Assets and Liabilities as on 30.09.2021.
- 3) Cash flow statement for the period ended 30.09.2021 in annexure 1
- 4) The Company operates in single segment i.e. "Pharmaceuticals", and hence does not have any additional disclosures to be made under Ind As 108 on operating Segments.
- 5) Limited review has been carried out by the Statutory Auditors of the Company.

FOR & BEHALF OF BOARD OF DIRECTORS
AURO LABORATORIES LIMITED

SIDDHARTHA DEORAH
WHOLE TIME DIRECTOR
DIN NO. 00230796




Place : Mumbai
Date : 11.11.2021

Cash Flow Statement

(Rs. In Lakhs)

Particulars	For the Half year ended 30.09.2021		For the Half year ended 30.09.2020	
	Amount	Amount	Amount	Amount
A. Cash flow from operating activities				
Net Profit / (Loss) before extraordinary items and tax		250.93		502.10
Add: Adjustments for:				
Depreciation and amortisation	52.00		50.00	
Other Non Cash Items	(5.85)		(1.12)	
Finance costs	26.53	72.68	15.92	64.80
		323.61		566.90
Less: Adjustment for:				
Interest income	10.80		3.73	
Dividend income	0.19	10.99	-	3.73
Operating profit / (loss) before working capital changes		312.62		563.17
Changes in working capital:				
Adjustments for (increase) / decrease in operating assets:				
Inventories	(243.76)		267.62	
Trade receivables	122.06		(447.85)	
Loans and advances	(135.82)		(103.79)	
Other Bank Balance	-			
Other non-current assets	-	(257.52)		(284.02)
		55.10		279.15
Adjustments for increase / (decrease) in operating liabilities:				
Trade payables	69.41		20.71	
Other current liabilities	(84.16)		45.97	
Other long-term liabilities				
Short-term provisions	(28.60)		75.45	
Long-term provisions	-			
		(43.35)		142.13
		11.75		421.28
Cash flow from extraordinary items		-		-
Cash generated from operations		11.75		421.28
Net income tax (paid) / refunds		-		-
Net cash flow from / (used in) operating activities (A)		11.75		421.28
B. Cash flow from investing activities				
Capital expenditure on fixed assets, including capital advance	(84.00)			
Proceeds from sale of fixed assets	(1.23)		(23.26)	
Interest received				
- Others	10.80		3.73	
Dividend received				
- Others	0.19		-	
		(74.24)		(19.53)
Net income tax (paid) / refunds		(73.07)		(138.08)
Net cash flow from / (used in) investing activities (B)		(147.31)		(157.61)




C. Cash flow from financing activities			
Proceeds from long-term borrowings			
Repayment of borrowings & Net increase / (decrease) in working capital borrowings	486.43		38.19
Proceeds from other short-term borrowings			
Repayment of other short-term borrowings	(27.50)		(18.12)
Finance cost	(26.53)		(15.92)
		432.40	4.15
Cash flow from extraordinary items			
Net cash flow from / (used in) financing activities (C)		432.40	4.15
Net increase/(decrease) in Cash & cash equivalents (A+B+C)		296.84	267.82
Cash and cash equivalents at the beginning of the year		1,453.63	568.41
Cash and cash equivalents at the end of the year		1,750.47	836.23

FOR & BEHALF OF BOARD OF DIRECTORS

AURO LABORATORIES LIMITED

SIDDHARTHA DEORAH
WHOLE TIME DIRECTOR
DIN NO. 00230796



Place : Mumbai
Date : 11.11.2021



KHURDIA JAIN & CO.
CHARTERED ACCOUNTANTS

To,
The Board of Directors,
Auro Laboratories Limited.

We have reviewed the standalone Ind AS financial results of Auro Laboratories Ltd. ("the company") for the Quarter ended September 30, 2021, attached herewith, being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016.

This Statement is the responsibility of the Company's Management and had been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards, prescribed under section 133 of the Companies Act 2013 read with relevant rules issued thereunder and accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statements prepared in accordance with generally accepted accounting standards in India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in term of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Khurdia Jain & Co.
Chartered Accountants



Sampat Khurdia
Partner

Membership No. 033615

Firm Reg. No. 120263W

Place: Mumbai

Date: 11th November, 2021

UDIN: 21033615AAAAED2649

